Drug intelligence / Profile preview

NV-HIV-1

Development stage: Preclinical
Lead developer: NanoViricides
Modality: Nanoparticles → Drug Delivery Systems

Overview

NV-HIV-1 is a nanomedicine-based drug candidate developed by NanoViricides, with research and development performed by TheraCour. It is designed for the treatment of Human Immunodeficiency Virus (HIV) infections. The drug leverages nanomedicine technology licensed exclusively from TheraCour, aiming to combat viral diseases.

Targets

gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)

Beyond the preview

Go deeper on NV-HIV-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-HIV-1.

Explore the full profile